We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes did not have higher risk for ...

Dual therapy with metformin and GLP-1 RAs is associated with a lower risk for adiposity-related cancers and mortality than ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...

For patients with diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) don’t appear to increase suicidality over what’s seen with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or ...

NEW YORK (Reuters) - GlaxoSmithKline Plc will study combining its diabetes drug Avandia with a new class of DPP-4 medicines but does not believe its established drug is under threat, its chief ...

The study looked at how six major second-line diabetes medications affect heart health. And the results were troubling.

Reflux is more common in people on GLP 1 drugs and can itself cause cough. After removing these patients, GLP 1 users had a ...

AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...